Introduction: In Non-Hodgkin Lymphoma (NHL), bone marrow histology is the gold standard against which ancillary investigations such as immunophenotyping and gene rearrangement studies are interpreted. ere is currently no data on the reproducibility of histological ndings. is study was conducted to determine the rates of inter-and intraobserver agreement in histological detection of bone marrow involvement in the two major subtypes of NHL, Di use Large B-cell Lymphoma (DLBCL), and Follicular Lymphoma (FL).
e two commonest subtypes of Non-Hodgkin Lymphoma (NHL) are Di use Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) [1] . DLBCL is an aggressive lymphoma, comprising 30-40% of all cases of B-cell NHL, whereas FL is a low grade NHL, accounting for approximately 30% of B-cell NHL cases [1] . e diagnosis of lymphoma is made on histological assessment of tissue from the primary site of involvement; e.g.. lymph node or extranodal tissue [2] .
Once the diagnosis is established, staging investigations are performed to determine the extent of spread. is includes radiological assessment using computerised tomography (CT) scans, positron emission tomography, and bone marrow biopsy. Bone marrow (BM) assessment is performed routinely at initial diagnosis in both subtypes of NHL [2] and rates of involvement vary depending on the subtype of NHL. BM involvement is reported in DLBCL in 11-25% of cases [3, 4] and in up to 50% of cases with FL [5, 6] .
When assessing the ability of a test to be helpful clinically, it is important to ascertain that the interpretation of results is not a product of conjecture. Precision, as it pertains to agreement between observers (inter-observer agreement), is o en reported as a kappa statistic. Kappa is intended to give the reader a quantitative measure of the magnitude of agreement between observers [7] . e histological assessment of the BM is assumed to be reasonably reliable in the hands of experienced morphologists. Surprisingly, there is no objective data or evidence to support this. We therefore performed an inter-observer and intraobserver study using kappa statistic to test the hypothesis that there is a good degree of agreement amongst pathologists over time in the assessment of BM in cases with DLBCL and FL.
Materials and Methods
e reproducibility of histological assessment of BM was studied in randomly-selected cases of DLBCL and FL for whom bone marrow biopsy slides were available at e Canberra Hospital. Approval for the study was obtained from the Australian Capital Territory Health Human Research Ethics Committee. Forty cases of DLBCL were randomly selected using statistical methods by investigator, TC from an established database. A data search was instituted for FL cases and a random selection of 40 cases performed by investigator TC.
e BM slides of these cases were retrieved from archives. ese included aspirate and trephine biopsy slides. In our institution, slides performed on aspirate samples include at least two squash preparations, two trail preparations and one touch smear preparation. Trephine biopsies are routinely xed in formalin and decalci ed using nitric acid. Two Haematoxylin and Eosin stains, one Giemsa stain and a reticulin stain using sliver impregnation are prepared. A variable number of sections are cut from the same level -this variation depends on the operator and the biopsy specimen; however, usually for lymphoma cases, as far as possible, three to four sections are cut.
Slides were independently reported by two blinded hematologists (AM and DT) with at least seven years training in evaluating bone marrow aspirate and trephine biopsies. Parameters reported on each BM included cellularity (based on trephine biopsy), lymphomatous involvement on aspirate and trephine biopsy, number of lymphoid aggregates, cellular size of lymphocytes, % of the biopsy involved and presence or absence of brosis. Final conclusions of positive, negative or indeterminate for involvement were based on standardized Cheson criteria [8] . Cases positive on aspirate or trephine biopsy were considered positive for involvement.
Both hematologists drew their conclusions without any clinical data and without being aware of the previous reports or reports on ancillary investigations. is was used to assess for inter-observer variability. To assess for intra-observer variability, one hematologist (AM) reported the BM slides on the DLBCL cases a minimum of two weeks apart, and the other (DT) re-reported FL cases. In both cases, the haematologists were not aware of their previous results as cases were re-blinded by the independent investigator TC.
e kappa statistic, which is a measure of the agreement between two observers, was used to assess the agreement amongst the two hematologists. is agreement can range from -1.0 to +1.0; if there is perfect agreement, the value is 1.0, whereas if the observed agreement is what would be expected by chance alone, the value is zero. Kappa statistic is classi ed as follows: Almost perfect agreement -0.81 to 0.99, Substantial agreement -0.61 to 0.80, Moderate agreement -0.41 to 0.60, Fair agreement -0.21 to 0.4, Slight agreement -0.01-0.20, Less than chance agreement <0.01 [7] . Weighted kappa statistic was used for the discrete measures. Computation of results was performed by TC. All statistical analysis was performed by BS and DT using SPSS version 19.0. ere were 2 cases each with DLBCL and FL with missing data; these were excluded by the so ware during statistical analysis.
biopsy and the number of levels examined, was appropriate for Non-Hodgkin Lymphoma [9, 10] . e average length of the trephine biopsies was 18 ± 7 mm for DLBCL (Range 8-36 mm) cases and 19 ± 7.9 mm for FL cases (range 7-42 mm) ; the average number of levels examined was 4 ± 1.5 (range 1-7) for DLBCL and 4 ± 1.3 (range 2-8) for FL cases [ Table 1 ]. While these specimens were not consistently free of cortical bone, cartilage or connective tissue, these inclusions were not felt to impact signi cantly on adequacy of histological assessment. Table 2 shows the rates of involvement in aspirate and trephine samples for DLBCL and FL, as assessed by the two investigators at initial assessment and reassessment. Over the three assessments, rates of involvement on aspirate and trephine biopsy in DLBCL cases ranged from 3-11% (re ecting 1-4 +ve cases) and 11-16% (re ecting 4-6 +ve cases), respectively. Overall, eight cases were positive for involvement in aspirate and/or trephine samples with six cases positive in trephine biopsies +/-aspirate and an additional two cases +ve in aspirates only. Of these, three were concordant cases with large cell involvement; the remaining four had small cells in the bone marrow. Much higher rates of involvement were noted in trephine biopsies in FL cases [aspirate: 3-18%, re ecting 1-7 +ve cases, trephine: 37-40%, re ecting 14-15 cases]. Overall, 16 cases were positive for involvement with FL, with 15 cases +ve on trephine +/-aspirate, and one case +ve on aspirate alone. Of the trephine-positive cases, six were also positive in the aspirates. Rates of discrepancies in reporting (BM involved or not involved with lymphoma) between assessments ranged from ~3-11%.
A total of 10 FL cases ( ve aspirates and ve trephines) were identi ed as having discrepant results on initial assessment between the two investigators and/or on reassessment. Six DLBCL cases (three aspirates and four trephines with one case discrepant on both aspirate and trephine) were identi ed as having discrepant results either on initial assessment between the two investigators, or on reassessment. All discrepant results on trephine biopsies were evaluated in detail to determine the basis for classifying cases as involved or not involved for lymphoma. All FL cases had a trephine length of at least 16 mm, with two having < two levels examined. Two of the four trephines in DLBCL were <10 mm in length and had < two levels for examination. Reasons for inter-observer and intraobserver discrepancies ranged from di erences in the presence or absence of brosis, size of aggregates, presence of large cells admixed with small cells and location of aggregates (intertrabecular vs. paratrabecular location). e most discrepant case was reported as exhibiting a 30% involvement with large lymphoma cells in a paratrabecular location in one assessment but as not involved on another assessment. No speci c patterns could be identi ed between FL and DLBCL cases or between inter-observer and intra-observer analysis.
Weighted kappa results showed variable inter-observer agreement in FL: aspirate=0.48 and trephine=0.77. Rates of inter-observer agreement in DLBCL were as follows: aspirate=0.52 and trephine= 0.77. Intra-observer agreement in FL was noted to be: aspirate=0.55 and trephine=0.94. Intraobserver agreement in DLBCL was observed to be as follows: aspirate=0.65 and trephine=0.60.
Intra-observer agreement in FL was noted to be: aspirate=0.55 (91.5% agreement) and trephine=0.94 (97.3% agreement). Intra-observer agreement in DLBCL was observed to be as follows: aspirate=0.65 (97.2% agreement) and trephine=0.60 (89.4% agreement).
Discussion
Most of the literature on reliability studies in lymphoma and leukemia centre on diagnostic samples rather than on staging samples [11] [12] [13] [14] . e Non-Hodgkin's Lymphoma Classi cation Project found a diagnostic accuracy of at least 85% for major lymphoma subtypes and diagnostic reproducibility of 85% [15] . e diagnostic accuracy of BM, when it is the primary site of extranodal involvement in NHL, has been reported to be ~85%, with low-grade lymphomas reported to have a diagnostic accuracy of 93% and high grade lymphomas that of ~84% [16] .
When assessed for staging, lymphomatous involvement of BM has prognostic signi cance, as it increases the stage of disease to stage IV. e International prognostic Index (IPI) [17] and the Follicular Lymphoma International Prognostic Index (FLIPI), [18] used in aggressive and low-grade lymphomas, respectively, use BM assessment as one of the tools to determine the stage of disease. Although the use of additional investigations to establish clonality on BM samples has increased, these tests are still o en interpreted in the context of histology as the gold standard. Despite the signi cance of BM assessment in staging lymphoma, there is no literature assessing its reliability in any of the subtypes of NHL. As far as we are aware, this is the rst study reporting on the reliability of histological detection of lymphoma in the bone marrow in patients with DLBCL and FL, the two commonest subtypes of NHL. e subjective interpretation of histology in staging bone marrows was apparent in the low levels of agreement across both subtypes of lymphoma; this was least so in the reporting of the trephine biopsies in the patients with FL.
Morphologic detection of lymphoma in the bone marrow can be di cult as compared with non-BM tissue because of several reasons inherent to the lymphoma, the tissue being examined or the pathologist. Patterns of involvement in di erent subtypes of NHL vary signi cantly. FL cells characteristically localize loosely to paratrabecular areas with signi cant brosis, making involvement relatively easy to identify. e cytology of cells mirrors that seen in lymph nodes; however, the follicles, which are o en seen well on lymph nodes, are rarely seen on BM trephines [1, 9] . In contrast, BM involvement in DLBCL may be quite variable. It may be concordant; i.e., large cells in BM, or discordant; i.e., presence of small cells in BM with only occasional large cells. Discordant involvement has a propensity to be confused relatively easily with benign lymphoid in ltrates. Distinguishing concordant involvement from discordant is important as concordant involvement is associated with a poorer prognosis [3, 19, 20] . Moreover, the malignant cells in DLBCL can occur in the form of di use con uent areas, which are relatively easy to identify or scattered large malignant cells, particularly in certain subtypes of DLBCL such as T-cell rich B-cell lymphoma or Anaplastic large B-cell lymphoma, which may be a lot more di cult to distinguish amongst other bone marrow precursors [1, 21] .
Rates of detection of lymphoma on bone marrow aspirates are notoriously low [22, 23] . is may be because of dilution of bone marrow and therefore of possible lymphoma cells by peripheral blood. In cases heavily in ltrated with lymphoma, conversely, the presence of brosis may result in a dry tap and a negative bone marrow aspirate [22] . While lymphoid aggregates are relatively easy to identify on trephine biopsy, the diagnosis of lymphoma on the aspirate is based on cytology of individual cells with a consequent increase in variability. Higher rates of agreement were seen in bone marrow trephines as compared with BM aspirates.
Rates of detection of lymphoma in bone marrow trephines can be quite variable because of inadequate sampling. Previously, a number of studies advocated the use of bilateral bone marrow biopsies, [8, 22, 24] although this is no longer felt necessary [2] . Guidelines prescribe a minimum trephine length of 16-20 mm [9, 25] . It is, however, o en impracticable to perform a repeat biopsy if this minimum length is not obtained.
e number of levels examined can also impact on the rate of detection of lymphoma. For example, in DLBCL, four levels are reported to be a requisite minimum [10] . ere is no similar literature available in FL or other subtypes of NHL. In the absence of clear published evidence, four levels were examined for cases with FL. In our cohorts of DLBCL and FL, the mean trephine length and number of levels examined were compliant with recommendations. Although numbers are too small to make meaningful conclusions, it is worth noting that two of the four discordant DLBCL cases had a lower than recommended trephine length.
Many reactive conditions cause benign lymphoid aggregates to form in the bone marrow, which can confound the detection of lymphoma. Histologically, distinguishing these benign lymphoid aggregates from malignant in ltration can be di cult, although features such as size of aggregates and cells, localization, and the presence of increased reticulin are used to distinguish the two [8, 26, 27] . As evidenced in this study, there is a great degree of subjectivity in making such a decision in an individual case -this is likely to be particularly evident in cases with small proportions of lymphocytes. In this study, 10 of the 16 cases with discordant results had <5% involvement with lymphoma cells.
e ICSH guidelines go a long way in establishing standardization in performing and reporting of bone marrow biopsies [25] . However, as these do not adequately cover lymphoma diagnosis speci cally, in our study, the Cheson criteria were used to ensure standardization of reporting of lymphomatous involvement between pathologists over time [8] . BM was reported as positive or negative for involvement, with focus on speci c and pre-determined details such as degree, location (paratrabecular vs. intertrabecular) and presence of large vs. small cells included in the report.
A human factor that contributes to variability in reporting is reporting bias. Clinical details, such as knowledge of the blood count and the clinical/radiological staging results, are o en known to the reporting pathologist. is unknowingly leads to a bias in judgment. An even greater contributor to bias is knowledge of results of ancillary investigations. Traditionally, ancillary investigations performed on the BM in staging lymphoma are interpreted against histological diagnosis, which is still used as the gold standard [28, 29] . While a negative result on ancillary investigations such as ow cytometry and immunohistochemistry may convince reporting histopathologists against morphological involvement, literature suggests that this may not necessarily be the case. Lack of concordance between histology and ow cytometry, [30] [31] [32] [33] [34] as well as IHC and histology, is well described [21, 35, 36] . Similar irregularities have been shown between histological ndings and molecular studies using gene rearrangement studies [37, 38] . While there are no studies comparing the signi cance of BM and radiological staging, the perceived limited application of the results of BM staging over radiological staging in the management of patients with lymphoma has the potential to introduce a degree of complacency and reduce the reliability of histological diagnosis. ese biases were factored into our study by blinding both pathologists to the clinical data as well as to data from ancillary laboratory and radiological investigations. e obvious limitations of the current study are small cohort of cases and a rather ideal diagnostic situation that may not re ect real-life, where samples may be inadequate and reporting pathologists may not be blinded to clinical data and data from ancillary investigations. is ideal diagnostic situation was, however, necessary for a reliable study of the precision of histological analysis. is study is also important because it explains, to some extent, the widely reported range of BM involvement in studies of FL and DBCFL. It also raises important questions of how best to de ne BM involvement within prognostic scores such as IPI and FLIPI.
It has been previously suggested that staging in DLBCL can be improved by adding results of ancillary investigations to histological assessment. Of 156 DLBCL cases, immunophenotyping ( ow cytometry and immunohistochemistry) upstaged 30 (19.2%) cases to stage IV. A further eight (5.1%) cases were upstaged using molecular studies. A change in IPI was noted in E362 (14.1%) cases on immunophenotyping and molecular testing. A revised IPI model, using immunophenotyping with histological assessment, showed better di erentiation between IPI categories as compared to baseline IPI using histology alone [4] . e results from the current study help explain the above ndings, and further suggest that histological assessment alone is unreliable and is best used in conjunction with ancillary investigations, which, lending themselves to objective data, are likely to be more reliable. Larger multicentre studies are required to determine the impact of using multiple laboratory modalities to detect bone marrow involvement on prognostic indices.
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